52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Vertex Pharma Establishes Wholesale Acquisition Cost For Trikafta Of $311,503 On An Annual Basis
FDA Approves TRIKAFTA To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older Who Have At Least One F508del Mutation
FDA Approves New Breakthrough Therapy For Cystic Fibrosis
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
Biotechnology & Drugs
50 Northern Ave
Jeffrey M. Leiden
Chairman of the Board, President, Chief Executive Officer
Charles F. Wagner
Chief Financial Officer, Executive Vice President
Michael J. Parini
Executive Vice President, Chief Legal and Administrative Officer
Executive Vice President - Global Research, Chief Scientific Officer
Stuart A. Arbuckle
Executive Vice President, Chief Commercial Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Vertex Pharmaceuticals Inc has priced its three-drug combination for cystic fibrosis (CF) at $311,503 per year, after winning early U.S. approval on Monday.
The U.S. Food and Drug Administration approved Vertex Pharmaceuticals Inc's combination treatment for a rare condition called cystic fibrosis, the agency said on Monday.
Vertex Pharmaceuticals Inc <VRTX.O> said on Tuesday it would buy privately held Semma Therapeutics for $950 million in cash with an aim to develop potentially curative stem-cell based treatments for diabetes.
Vertex Pharmaceuticals Inc said on Tuesday it would buy privately held Semma Therapeutics for $950 million in cash to develop stem-cell based treatments for diabetes.
Vertex Pharmaceuticals Inc said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190606:nBw4wRKsa on Thursday it would acquire privately held Exonics Therapeutics for an upfront payment of $245 million and potential milestone payments...
Vertex Pharmaceuticals Inc said on Thursday it will apply for regulatory approval later this year for its triple combination of drugs to treat life-shortening genetic condition cystic fibrosis.
* CINCOR PHARMA IN-LICENSES ALDOSTERONE SYNTHASE INHIBITOR, CIN-107, AND CLOSES $50 MILLION SERIES A FINANCING
* CRISPR THERAPEUTICS AND VERTEX ANNOUNCE FDA FAST TRACK DESIGNATION FOR CTX001 FOR THE TREATMENT OF BETA THALASSEMIA Source text for Eikon: Further company coverage:
Vertex Pharmaceuticals Inc on Wednesday said its triple-combination treatment for cystic fibrosis led to significant lung function improvement in two late-stage studies, paving the way for a therapy that could eventually address 90 percent of people with the life-shortening...
Vertex Pharmaceuticals Inc said on Wednesday it had terminated the employment of its chief operating officer and interim chief financial officer, Ian Smith, citing "personal behavior" that violated its code of conduct.
Vertex Pharmaceuticals Inc said on Wednesday it had terminated the employment of its chief operating officer and interim chief financial officer, Ian Smith, citing personal behavior that violated its code of conduct.
Vertex Pharmaceuticals Inc said on Tuesday that its triple combination therapy showed significant improvement in lung function in patients with cystic fibrosis (CF) in two late-stage clinical studies, sending its shares up 5 percent.
U.S. health regulators have expanded the use of one of Vertex Pharmaceuticals Inc's cystic fibrosis drugs to include patients aged between 12 months and 24 months.
Vertex Pharmaceuticals Inc topped analysts' forecasts for quarterly profit on Thursday, led by stronger-than expected sales of its latest cystic fibrosis drug as well as double-digit growth in sales of older treatments.
* VERTEX INITIATES PHASE 3 STUDIES OF VX-445, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS
Vertex Pharmaceuticals Inc's quarterly profit fell 15.1 percent, hurt by higher research and development spending.
* COMPANY REITERATES FULL-YEAR 2018 TOTAL CF PRODUCT REVENUE GUIDANCE OF $2.65 BILLION TO $2.80 BILLION
* VERTEX PHARMACEUTICALS INC SAYS CEO JEFFREY LEIDEN'S FY 2017 TOTAL COMPENSATION WAS $17.3 MILLION VERSUS $17.4 MILLION IN FY 2016 - SEC FILING Source text (https://bit.ly/2JVKbq6) Further company coverage:
* VERITAS PHARMA ENTERS INTO SHARE PURCHASE AGREEMENT WITH 3 CARBON EXTRACTIONS INC. Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
* VERTEX PHARMACEUTICALS INC - CEO JEFFREY LEIDEN'S 2017 TOTAL COMPENSATION WAS $17.2 MLN VS $17.4 MLN IN 2016 - SEC FILING Source text - https://bit.ly/2uQs5Cx Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.